Mounjaro (Injection)

Overview

Mounjaro® (tirzepatide) is a brand-name, FDA-approved once-weekly injection from Eli Lilly, indicated to improve blood-sugar control in adults with type 2 diabetes. It is prescribed only when a licensed U.S. provider determines it is clinically appropriate for you, and it is dispensed by an independent licensed pharmacy.

How it works

Tirzepatide activates both the GIP and GLP-1 receptors. These receptors are involved in insulin response, gastric emptying, and appetite regulation. Your provider will discuss what to expect in your individual situation.

At a glance

Active ingredient

Tirzepatide

Manufacturer

Eli Lilly

Drug class

Dual GIP and GLP-1 receptor agonist

Form

Prefilled injection pen

Administration

Once weekly, self-injected as directed by your provider

Dosing

Determined by your provider, with gradual titration

FDA status

FDA-approved (May 2022) for type 2 diabetes

Prescription

Required — issued only after licensed provider review

Storage

Refrigerate 36–46°F (2–8°C); protect from light

What is included with MedicLab